Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies
Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunology, Immunotherapy 2018, 67: 1833-1844. PMID: 30191256, PMCID: PMC6249064, DOI: 10.1007/s00262-018-2241-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalComorbidityDisease ManagementFemaleHealth Care SurveysHumansImmunotherapyMaleMelanomaMiddle AgedMolecular Targeted TherapyNeoplasm StagingOdds RatioProtein Kinase InhibitorsProto-Oncogene Proteins B-rafRegistriesSymptom AssessmentUnited StatesYoung AdultConceptsStage 4 melanomaOverall survivalInitial approvalCutaneous melanomaLandmark survival analysisSubstantial clinical efficacyImproved overall survivalMetastatic cutaneous melanomaNational Cancer DatabaseStage 4 diseaseCheckpoint blockade immunotherapySurvival of patientsRisk-adjusted analysisBlockade immunotherapyCheckpoint blockadeNovel immunotherapiesMultivariable analysisClinical efficacyMetastatic melanomaNational cohortCancer DatabaseUninsured patientsClinical trialsPatientsSurvival analysis